07 September 2020 : Clinical Research
Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
Xianghua Zeng123CDEG, Shicong Zhu12BCD, Cheng Xu4CF, Zhongyu Wang12CD, Xingxing Su12CD, Dong Zeng12CD, Haixia Long12AF*, Bo Zhu12AGDOI: 10.12659/MSM.922576
Med Sci Monit 2020; 26:e922576
Table 4 Tumor response in patients with NSCLC treated with PD1 inhibitors.
| Response evaluation | All (n=66) | CCI | SCS | ||
|---|---|---|---|---|---|
| <1 (n=38) | ≥1 (n=28) | <8 (n=41) | ≥8 (n=25) | ||
| Disease control rate | 54 (81.8%) | 36 (94.7%) | 18 (64.3%) | 34 (82.9%) | 20 (80.0%) |
| Overall response rate | 24 (36.4%) | 14 (36.8%) | 10 (35.7%) | 16 (39.0%) | 8 (32.0%) |
| Complete response | 0 | 0 | 0 | 0 | 0 |
| Partial response | 24 (36.4%) | 14 (36.8%) | 10 (35.7%) | 16 (39.0%) | 8 (32.0%) |
| Stable disease | 30 (45.4%) | 22 (57.9%) | 8 (28.6%) | 18 (43.9%) | 12 (48.0%) |
| Progressive disease | 12 (18.2%) | 2 (5.3%) | 10 (35.7%) | 7 (17.1%) | 5 (20%) |
| NSCLC – non-small cell lung cancer; PD1 – programmed cell death protein 1; CCI – Charlson comorbidity index; SCS – simplified comorbidity score. | |||||